Mesa Laboratories, Inc. (MLAB) To Go Ex-Dividend on November 29th

Mesa Laboratories, Inc. (NASDAQ:MLAB) declared a quarterly dividend on Wednesday, October 2nd,Zacks Dividends reports. Investors of record on Friday, November 29th will be given a dividend of 0.16 per share by the medical instruments supplier on Monday, December 16th. This represents a $0.64 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend is Friday, November 29th.

Mesa Laboratories has a payout ratio of 6.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Mesa Laboratories to earn $8.29 per share next year, which means the company should continue to be able to cover its $0.64 annual dividend with an expected future payout ratio of 7.7%.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $116.45 on Wednesday. The firm’s 50 day simple moving average is $121.12 and its 200-day simple moving average is $114.49. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65. Mesa Laboratories has a one year low of $83.68 and a one year high of $141.17.

Insider Transactions at Mesa Laboratories

In related news, CEO Gary M. Owens sold 2,518 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the sale, the chief executive officer now owns 45,888 shares of the company’s stock, valued at $5,213,794.56. This represents a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction on Friday, September 13th. The stock was sold at an average price of $125.00, for a total transaction of $187,375.00. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MLAB shares. Wells Fargo & Company initiated coverage on Mesa Laboratories in a research report on Tuesday, August 27th. They set an “underweight” rating and a $120.00 target price for the company. StockNews.com lowered shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Finally, Evercore ISI raised their target price on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.